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Background: The NHLBI has not developed clinical practice guidelines since 2007. As a result, multiple organizations
have released competing guidelines. This has created confusion and debate among clinicians as to which recommen-
dations are most applicable for practice.
Objectives: To explore preliminary attitudes, awareness, and usage of clinical practice guidelines in practice and teach-
ing for hypertension, dyslipidemia and asthma among clinical pharmacists.
Methods: Clinical pharmacists across the US were surveyed electronically over a two week period in Spring 2019 re-
garding utilization and knowledge of practice guidelines for hypertension, dyslipidemia, and asthma. Clinical cases
were included to evaluate application of guidelines. Descriptive statistics, Chi-square analysis, and Wilcoxon signed-
rank test were conducted. Statistical significance level was set to 0.01 to account for multiple tests conducted on the
same survey participants.
Results: Forty-eight, 34, and 28 pharmacists voluntarily completed hypertension, dyslipidemia, and asthma survey
questions, respectively. Interactions by disease state (p < 0.001) revealed more pharmacists (93%) reporting to
have≤50% patient load in managing asthma and more pharmacists (95%) had read the full summary/report of the
most recent hypertension guideline. Primary reasons why the most recent guideline was not selected were also signif-
icantly different by disease state (interaction; p < 0.001). For dyslipidemia and asthma, pharmacists had a higher
mean rating of agreement (p< 0.007) in having the most confidence in the most recent as compared to older guide-
lines. Proportionally more clinical cases were answered correctly (interaction; p < 0.001) when pharmacists applied
the most recent guideline for hypertension (84%), while the opposite outcome was found for asthma (27%).
Conclusion: While more pharmacists selected the most recent guideline for practice and teaching, there was inconsis-
tent application of guidelines to clinical cases. Further studies with a larger representation of pharmacists are war-
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1. Introduction
For generations, the National Heart, Lung, and Blood Institute (NHLBI)
has issued clinical practice guidelines for the chronic management of blood
pressure, dyslipidemia, and asthma. Over the past 10–15 years, several
other organizations have developed guidelines of their own. This has re-
sulted inmultiple guidelines for individual diseases from different agencies
that often lack agreement. Complicating this, in 2013, theNHLBI declared a
refocus to “supporting and producing rigorous systematic reviews that can
then be used by other collaborating organizations to generate guideline
products that serve the public interest”.1 The long-trusted organization
would no longer publish clinical practice guidelines. As a result, newer
guidelines have been released with evolving evidence in the post-NHLBI
era, oftentimes frommultiple agencies. This has led to confusion among cli-
nicians as to which guideline is “best” or considered the gold standard
within disease states.
The NHLBI created the National High Blood Pressure Education Pro-
gram (NHBPEP) in 1977, charging the Joint National Committee (JNC) to
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develop hypertension guidelines. With emerging evidence from clinical tri-
als, new iterations were released over ensuing years, culminating in the
publication of JNC-7 in December 2003.2 By the time NHLBI declared
their withdrawal from guideline development, members of the JNC-8
working group, appointed in 2008, had already spent several years working
on the next iteration. Part of this panel submitted their work to a renowned
medical journal in an attempt to become the next U.S. hypertension guide-
line. This resulted in “The 2014 Hypertension Guideline,” sometimes re-
ferred to as “JNC-8”.3 Without endorsement by the NHLBI or other
professional organizations, there was significant controversy over these
recommendations.4 As originally intended, the American College of Cardi-
ology (ACC) and American Heart Association (AHA) collaborated with
NHLBI in 2014 to create the most recent comprehensive hypertension
guideline,5 which was released in December 2017 (ACC/AHA 2017).
In 1985, the NHLBI introduced the National Cholesterol Education Pro-
gram (NCEP) and the adult treatment panel (ATP) to publish their first cho-
lesterol treatment guidelines, which were released in 1988.6 In 2004, lead
author, Scott Grundy, published the final version of ATP-III, with tradi-
tional emphasis on achieving LDL-cholesterol goals.7 Following the an-
nouncement from NHLBI and unlike the “JNC-8” authors, the ATP-IV
panel joined the ACC/AHA expert panel to complete new recommenda-
tions. Lead author, Neil Stone, released these guidelines in 2013, introduc-
ing major changes to the traditional practice philosophy.8 Instead of
LDL-cholesterol goals, proper statin intensity became the focus. In 2014,
in response to the dynamic changes, the National Lipid Association (NLA)
published recommendations9 which largely resembled an evolved ATP-III
document, even including Scott Grundy as a co-author, to provide a tradi-
tional alternative to the new philosophy introduced in the ACC/AHA
2013 guidelines. The U.S. Preventive Services Task Force (USPSTF) pub-
lished updated guidance in 2015 on “Statin Use in Primary Prevention of
Cardiovascular Disease in Adults”.10 ACC released the “Expert Consensus
Decision Pathway” update regarding non-statin therapy in 2016,11
followed by a “focused update” in 201712 to highlight new data from the
literature. This was endorsed by the NLA and started to combine treatment
philosophies. Most recently, both Scott Grundy and Neil Stone published
the ACC/AHA 2018 guidelines; continuing to bring the practitioners of
each philosophy together for common consensus.13
The NHLBI convened the National Asthma Education and Prevention
Program (NAEPP) to release their first set of guidelines “The Expert Panel
Report” in 1991, with updates in 1997 (EPR-2), 2002 (update of EPR-2),
and 2007 (EPR-3).14,15 In 1993, NHLBI collaborated with theWorld Health
Organization to create the Global Initiative for Asthma (GINA), with annual
updates since 2002.16 However, U.S. practitioners tended to defer to the
EPR-3, many not acknowledging the international GINA guidelines. Despite
GINA's efforts, many countries still suffered suboptimal asthma manage-
ment. This motivated a major revision in 2014 reflecting new asthmaman-
agement evidence and algorithms to enhance implementation, resulting in
GINA 201816 and subsequent annual iterations. In December 2020, NHLBI
released the long-awaited update to its 2007 asthma guidelines.
1.1. Rationale
With the evolution and, sometimes controversy, over these guidelines,
there is discord regarding standard use among clinicians. Staying-up-to-
date is increasingly challenging for pharmacists as their role continues to
evolve as medication therapy experts. Continuing education is a require-
ment of the pharmacy profession; however, studies have suggested that
continuing education doesn't necessarily change behavior or lead to better
patient outcomes.17 The pharmacy profession has implemented a continu-
ous professional development (CPD) approach to teaching life-long learn-
ing in US pharmacy programs, although this is in the early stages of
adoption. This is defined as an outcomes-focused learning cycle focused
on improving professional practice performance.18 In time, this method
may be applied to continuing education programs to help pharmacists eval-
uate guideline appropriateness and guide optimal guideline selection.
Consequently, approaches to staying updated with the latest literature
likely are still evolving and may not always be effective.
There are many unknowns when it comes to the current use and appli-
cation of practice guidelines. These include, what factors do clinical phar-
macists use to determine which new guideline is optimal for use?
Individuals are likely to hold varying opinions and biases. Should practi-
tioners simply use the most recent versions? Should they only use those en-
dorsed by certain organizations? Which guidelines have included the most
reliable evidence? Do practitioners only use new versions of guidelines they
are already familiar with? It is important to inform clinical pharmacists of
national practice trends in an effort to end discord among those in the pro-
fession and provide optimal patient care. Guidelines aremeant to be used to
assist with making proper clinical judgments, so a pharmacist must choose
which one seems to be the best for that individual's practice. Therefore, the
objective of this exploratory study is to identify attitudes, awareness, and
usage of clinical practice guidelines for hypertension, dyslipidemia and
asthma among US clinical pharmacists since the withdrawal of the NHLBI
from guideline development, in order to gain initial perspectives on factors
influencing guideline selection from pharmacists across the country.
2. Methods
The University of Nebraska Medical Center (UNMC) and Southwestern
Oklahoma State University (SWOSU) Colleges of Pharmacy jointly con-
ducted this study. The study received IRB approval (017–19-EX) from
UNMC in January 2019.
2.1. Design
A survey was created to determine demographics of participating clini-
cal pharmacists; utilization and knowledge of guidelines for hypertension,
dyslipidemia, and asthma; and ability of guideline application to clinical
cases for each disease state [Appendix A]. This survey was designed to be
administered at one-time as a cross-sectional, observational study to gain
an initial snapshot of current guideline practices. There were 58 potential
questions for the participants to answer, although they could choose to
skip an entire topic (e.g. asthma) if they did not have clinical experience
within that particular field. The format was a mixture of multiple choice
and fill in the blank questions. For hypertension, pharmacists could select
from JNC 7 (2003), JNC 8 (2014), or ACC/AHA (2017) guidelines; for dys-
lipidemia, choices included ATP III (2004), ACC/AHA (2013), NLA (2014),
USPTSF (2016), ACC (2017), and ACC/AHA (2018); for asthma, the only
two choices were ERP-3 (2007) and GINA (2018). Each disease state gave
the pharmacist the option to type in their own preferred guideline in the
event that it was not one of the pre-specified guidelines. Four cases were in-
cluded in the survey for hypertension (as compared to one each for dyslip-
idemia and asthma) to incorporate the variety of patient histories and
characteristics which would change the case answers.
Questions weremodeled after previously validated surveys in studies by
Virani19 and Bucheit,20 which surveyed clinicians' understanding of choles-
terol guidelines. Modifications weremade to include relevancy to hyperten-
sion and asthma guidelines and clinical cases were created for all three
disease states. Two of the investigators, who are practicing clinical pharma-
cist faculty at different institutions with experience in managing and teach-
ing these three chronic disease states, constructed cases commonly
encountered in practice, but which would have different solutions based
on the guideline used. To assess the validity of the current survey, a group
of ten local clinical pharmacists were consulted to review and pilot the sur-
vey to assess for appropriateness and to identify any common survey errors
such as leading questions. The pilot data demonstrated consistent compre-
hension of questions among testers, as expected due to previous validation.
The pilot datawas not included in the analysis of thefinal data for the study.
2.1.1. Participants and setting
This study utilized a voluntary sample design. The survey was emailed
to approximately 2400 members of the American College of Clinical
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Pharmacy (ACCP) Ambulatory Care Practice and Research Network (PRN).
ACCP is a leading organization in clinical pharmacy practice, as nearly two-
thirds have completed at least one year of residency training and two-thirds
are Board certified by the Board of Pharmacy Specialties.21 TheAmbulatory
Care PRN is comprised of clinical pharmacists with an emphasis on the pro-
vision of primary care for chronic diseases. This national organization is
likely to encompass clinical pharmacists who have direct experience in
managing hypertension, dyslipidemia and/or asthma. In adherence with
the Ambulatory Care PRN rules for administration of electronic surveys,
the survey was open to potential participants for a two-week period (Janu-
ary 28–February 10, 2019). The PRN members were initially emailed the
survey link with a brief description of the study. A reminder email was
sent as the two-week period neared its end.
Surveys were administered using Qualtrics software (Provo, UT), an on-
line software platform used for data collection and analysis. This enabled
the survey instrument to be distributed electronically and remotely to
ACCP PRN pharmacists across the nation. At the start of the survey, poten-
tial study participantswere providedwith the purpose, sponsorship, and ex-
pectations of the study. They were also informed that there was no penalty
for incorrect answers or non-participation. By proceeding with the survey,
PRN members implied their informed consent to participate in the study.
All submissions were anonymous, and all question responses were optional.
No incentive was provided for participation to further maintain anonymity
of survey respondents, whichwas important tominimize potential response
bias.
2.1.2. Statistical analysis
Analyses were conducted for the subset of pharmacists who self-
identified their practice within a particular disease state, and a pharmacist
could answer questions formore than one disease state. Inter-response rates
for disease states were determined. Data were summarized via descriptive
statistics using means and standard deviations for age and frequencies
and percentages for nominal responses. Categories were collapsed for
time in practice (≤10 years or > 10 years) and to estimate the percentage
of patients with whom they work to manage each disease state (≤50% or
> 50%). States in which pharmacists practiced were grouped into four re-
gions (Northeast,Midwest, South, and Pacific/West) according to the statis-
tical groupings of the U.S. Census.22
Univariate Chi-square analyses were conducted to compare results for
the most recent guideline to older guidelines as selected by pharmacists
or evaluate differences within each disease state. Expected frequencies
were set to be equal among categories. Bivariate Chi-square analysis was
used to test for interactions between disease states and other categorical
variables. Expected frequencies were determined from the data using prob-
ability calculations.
Pharmacists rated their level of agreement to the statement, “I have the
most confidence in the ___ guideline” using a five-point Likert scale of
strongly agree (valued at 5) to strongly disagree (valued at 1). All pharma-
cists had the opportunity to answer this question for themost recent and for
older guidelines. The Wilcoxon signed-rank test was used to compare re-
sults between the most recent guideline to older guidelines as rated by
the same set of pharmacists. Results were summarized using means and
standard deviations.
Statistical significance was set to 0.01 to account for the increased like-
lihood of finding significant outcomes when conducting multiple tests on
the same data set. The n of 57 participants needed for the study was deter-
mined from the results of Bucheit,20 and an online calculator23 was used for
sample size by inputting the proportion of pharmacists who were able to
identify the four statin benefit groups (72%) versus a population value of
50% with a dichotomous primary endpoint. Results by Virani,19 the other
study used to create the survey for this study, were not applied to determine
sample size due to there being an equal number of pharmacists who were
able to identify the four statin groups. Due to the lack of control over sample
sizewith a voluntary response design, the n needed tofind a statistically sig-
nificant outcome of pharmacists who selected the most recent guideline for
treating hypertension, dyslipidemia, and asthma were also determined
a posteriori using an online calculator for sample size23 by inputting the pro-
portion found for the study group versus a population value of 50% with a
dichotomous primary endpoint. All sample size calculations employed an
alpha of 0.01 and 80% power. All data were analyzed using JASP (Version
0.11.0) [JASP Team (2019), Amsterdam, the Netherlands].
Confidentiality of online data was maintained by not generating any
hard copies of the raw data and by safeguarding electronic files on a pass-
word protected computer in password protected files. No participant
names were gathered from the survey, and potential identifying informa-
tion such as gender, age, and location (i.e., state and primary practice set-
ting) were analyzed and reported as separate factors. Although Qualtrics
does provide an IP address, this information was omitted from working
data files and was not used for any purpose. No individual responses were
reported, and items having smaller responses (i.e., an individual survey re-




Fifty-four pharmacists responded, resulting in a 2.3% response rate.
Most pharmacists (89%) completed survey questions for hypertension
(n = 48) as compared to dyslipidemia (n = 34; 63%) and asthma (n =
28; 52%). Thirty pharmacists who completed hypertension questions also
completed those for dyslipidemia, and 27 pharmacists who completed dys-
lipidemia questions also completed those for asthma. Overall, 23 pharma-
cists completed questions for all three disease states, and 35 pharmacists
completed questions for two of the three disease states.
The average age of all survey participants was 34.8 ± 7.7 years, and,
across disease states, proportionally more pharmacists practiced ≤10
years (p ≤ 0.121) (Table 1). Significantly more female pharmacists (p <
0.008), more pharmacists from a Family Practice/Primary Care clinic
(p < 0.001), and more pharmacists both teaching in classrooms and
precepting students (p< 0.001) completed survey questions across disease
states. Across disease states, more pharmacists tended to hold a BCACP cer-
tification (p < 0.098) and proportionally more pharmacists were from the
Midwest (p = 0.050). However, no differences were detected for other
board certifications (p > 0.386) or among practice settings (p > 0.836).
The only significant interaction for demographics (p=0.005)was detected
between disease state and estimated percentage of patients with whom
pharmacists worked to manage each disease state (>50% vs. ≤50%); this
was due to significantly more pharmacists reporting to have≤50% patient
load in managing asthma (p < 0.001) as compared to hypertension and
dyslipidemia.
3.1.1. Guideline selection and awareness for practice
Proportionally more pharmacists selected the most recent guideline for
treating hypertension (ACC/AHA 2017 at 65%; p = 0.043), dyslipidemia
(ACC/AHA 2018 at 62%, p = 0.170), and asthma (GINA 2018 at 67%;
p = 0.083) in practice as compared to using older guidelines (Table 2).
Older guidelines selected for hypertension consisted of only JNC-8 (2014)
and for asthma, only ERP-3 (2007). The 38% of pharmacists who selected
older guidelines for dyslipidemia in practice consisted of 32% using ACC/
AHA (2013), 3% ACC (2017), and 3% AACE (2017). A posteriori
calculations23 revealed that a total sample size of 134 (versus 48), 207 (ver-
sus 34), and 102 (versus 27), of pharmacists practicing in hypertension,
dyslipidemia, and asthma disease states respectively, would have been
needed tofind significance at 1% alpha and 80% power using the outcomes
found in this study.
A significant interaction was found (p < 0.001) between disease state
and for length of time the most recent guideline has been used (Table 3);
there was a trend for the majority of pharmacists (74%) to have used the
most recent guidelines for hypertension for >1 year (p = 0.012) whereas
significantly fewer (9%) reported to have used the most recent guideline
to treat dyslipidemia for >1 year (p < 0.001) and half (50%) reported to
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have used the most recent asthma guideline for >1 year (P = 1.00). An-
other significant interaction was found (p < 0.001) between disease state
and pharmacists' level of awareness of the most recent guideline; almost
all (95%) pharmacists reported reading the summary/full report of the
ACC/AHA 2017 hypertension guidelines (p < 0.001). By comparison,
71% of pharmacists reported “reading the summary/full report” of the
ACC/AHA 2018 lipid guidelines (P < 0.001), while less than half (43%)
reported “reading the summary/full report” of the GINA 2018 asthma
guidelines (p = 0.002). In addition, 23% and 43% of pharmacists for dys-
lipidemia and asthma, respectively, reported “to be aware of some of the
content of the most recent guidelines, but had not read the summary or
the full report”.
When asked why they selected the most recent guidelines, pharmacists
across all three disease states chose the top two reasons of “I agree with all
Table 1
Pharmacist and practice characteristics of survey respondents for each disease state.
Hypertension Dyslipidemia Asthma P value for the
interactiona
n = 48 n = 34 n = 28
Pharmacist characteristics
Age, mean years (SD)b 34.2 (6.7) 34.9 (6.4) 35.3 (8.3) 0.775
Gender, n (%)b 0.894
Female 38 (79) 27 (79) 21 (75)
Male 10 (21) 7 (21) 7 (25)
P value within disease state§ < 0.001 < 0.001 0.008
Time in practice, n (%)b 0.717
≤10 years 35 (73) 23 (68) 18 (64)
>10 years 13 (27) 11 (32) 10 (36)
P value within disease state § 0.001 0.036 0.121
Board certifications, n (%)b 0.990
BCACP 22 (48) 16 (50) 11 (42)
BCPS 11 (24) 9 (28) 8 (31)
Both BCACP and BCPS 5 (11) 3 (9) 3 (12)
None 8 (17) 4 (13) 4 (15)
No response 2 2 2
P value within disease state § 0.002 0.004 0.098
Other certifications, n (%)b 0.710
Yes 21 (44) 16 (47) 15 (54)
No 27 (56) 18 (53) 13 (46)
P value within disease state § 0.386 0.732 0.705
Practice characteristics
Practice specialty, n (%)b 0.882
Family practice/primary care 39 (81) 28 (82) 24 (86)
Other: ambulatory care, anticoagulation clinic, community, internal
medicine, managed care, pulmonology, women's health
9 (19) 6 (18) 4 (14)
P value within disease statec < 0.001 < 0.001 < 0.001
Practice setting, n (%)b 0.956
Academic Medical Center 14 (29) 7 (21) 6 (21)
Community Health Center 12 (25) 9 (26) 6 (21)
Physician Group Practice 12 (25) 9 (26) 9 (32)
Other: Community Pharmacy, Government Facility, Inpatient Community Hospital
(non-academic), Integrated Health System, Rural Pharmacy, Private Practice
10 (21) 9 (26) 7 (25)
P value within disease statec 0.881 0.950 0.836
Estimated percentage of patients the respondent works with to manage
the specific disease state, n (%)b
0.005
≤50% 28 (58) 21 (62) 26 (93)
>50% 20 (42) 13 (38) 2 (7)
P value within disease state § 0.240 0.145 < 0.001
Teaching responsibility, n (%)b 0.952
Academic Classroom 2 (4) 0 (0.0) 1 (4)
Precept Students 18 (38) 14 (41) 11 (39)
Both Academic Classroom and Precept Students 27 (56) 19 (56) 15 (54)
Do not teach 1 (2) 1 (3) 1 (4)
P value within disease state § < 0.001 < 0.001 < 0.001
Region of the United States in which practice, n (%)b,d 0.997
Midwest 20 (42) 12 (35) 11 (39)
Northeast 7 (15) 6 (18) 5 (18)
South 10 (21) 7 (21) 5 (18)
Pacific and West 11 (23) 9 (26) 7 (25)
P value within disease state§ 0.050 0.481 0.330
a Analysis of variance was conducted across disease states to evaluate whether mean age was different. Bivariate Chi Square Analysis investigated the interaction between
disease state and demographic characteristic using probability calculations. Counts for “No response” were not included in totals. Alpha was set to 0.01.
b SD=Standard Deviation; n=number; %=percentages calculated using the total n of responses, not including counts of “No response.” “Other” responseswerewritten
in by respondents.
c Univariate Chi Square Analysis was conducted within disease state to evaluate whether study demographics of the observed counts were different than expected if equal.
Counts for “No response” were not included in either statistical analysis or totals used to calculate percentages. Alpha was set to 0.01.
d States were grouped into regions as defined by the U.S. Census.22
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or most of the recommendations compared to other guidelines” and “I al-
ways reference themost recently published guideline” (Table 3); thesefind-
ings were significant (p<0.001). A significant interaction was found (p<
0.001) between disease state and the reasons why pharmacists did not se-
lect the most recent guideline. For hypertension, the top two reasons
were different from the other disease states; these included, “I do not
agree with the treatment recommendations made in these guidelines,”
and “I am aware of the data but do not believe that it constitutes a guideline
change as this time” (p< 0.001). In contrast, themain reason that pharma-
cists were not using the most recent guideline for dyslipidemia or asthma
was, “I am not very familiar with this guideline” (p = 0.002).
Across disease states, pharmacists had a higher level of agreement to the
statement that they “had most confidence in the most recent guidelines as
compared to older guidelines” for hypertension (p = 0.097), dyslipidemia
(p=0.001), and asthma (p=0.007) (Table 3). For dyslipidemia, no differ-
ence in ratings were foundwhen comparingmean agreement in confidence
for the older guidelines of ACC/AHA (2013) versus ACC (2017) (3.3± 1.1
versus 3.3 ± 0.9, respectfully; p = 0.893). Therefore, their ratings were
composited by pharmacist and compared against the corresponding phar-
macist rating for the most recent dyslipidemia guideline, ACC/AHA
(2018). No specific rating statement was available in the survey for AACE
(2017), due to this guideline having been typed in by one pharmacist as
their preferred guideline for dyslipidemia practice.
3.1.2. Guidelines selection for teaching
Significantly more pharmacists who taught hypertension (75%) re-
ported teaching the most recent guideline (p=0.003) (Table 2). Similarly,
proportionally more pharmacists taught the most recent dyslipidemia
(72%) and asthma (78%) guidelines (p<0.02). Two pharmacists reported
teaching a combination of the most recent and older guidelines for all three
disease states.
3.1.3. Guideline application to clinical cases
Participants were asked to apply guidelines to answer four clinical cases
for hypertension with the appropriate blood pressure (BP) goal, one clinical
case for dyslipidemia with the appropriate goal and treatment recommen-
dation, and one clinical case for asthmawith the appropriate treatment rec-
ommendation [Appendix A]. Significantly more pharmacists (67%; p <
0.001) reported applying the most recent guideline (ACC/AHA 2017) as
compared to older guidelines to answer the four hypertension survey
cases (Table 2). Proportionally more pharmacists (68%, p=0.088) applied
the most recent guideline (GINA 2018) to answer the asthma case. In con-
trast, only about half of the pharmacists applied the most recent guideline
(ACC/AHA 2018) as compared to older guidelines to answer the dyslipid-
emia case (54% versus 46%; p = 0.705). Of those using older guidelines
for the dyslipidemia case, 36% applied ACC/AHA (2013) and 10% ACC
(2017).
An interaction was detected (p< 0.001) between disease state and cor-
rectness of response based on which guideline was selected to answer clin-
ical cases (Table 4). There was a tendency (p = 0.011) for more
pharmacists to answer the four hypertension clinical cases correctly when
referencing the most recent guideline (84% correct) as compared to when
referencing the older guideline (65%). In contrast, there was a trend (p =
0.077) for fewer pharmacists to recommend a correct pharmacotherapeutic
agent when using the most recent guideline (53%) as compared to those
using older guidelines for dyslipidemia (85%). Significantly fewer pharma-
cists answered the asthma case correctly when using the most recent guide-
line (27%) as compared to using the older guideline (100%).
Overall application of the most recent and older guidelines was incon-
sistent within pharmacists. In evaluating pharmacist selection of the most
recent guidelines (Table 2), a numerically higher percentage of pharmacists
reported to teach the most recent guideline across disease states (weighted
average of 75%) as compared to practice (weighted average of 64%) or clin-
ical case application (weighted average of 65%). Proportionally fewer phar-
macists applied the most recent guideline to the dyslipidemia clinical case
(54%) as compared to hypertension and asthma cases. Several pharmacists
did not indicate specific guidelines for their recommendations across dis-
ease states, and 14% of the possible 192 recommendations were unan-
swered for the hypertension survey cases. For the hypertension clinical
cases, only 16 pharmacists consistently used the most recent guideline
across all four clinical cases, while 8 pharmacists used the older guideline
for all cases and 16 pharmacists used a combination of the most recent
guideline with the older guideline and/or selected no specific guideline.
The breakdown of pharmacists answering each hypertension clinical case
revealed a lower percentage of pharmacists using the most recent guideline
to answer case 4 as compared to the previous three cases (46% versus 63%
weighted average), while more pharmacists did not specify the guideline
they used for case 4 (29% versus 6% weighted average). Proportionally
fewer pharmacists answered hypertension case 2 correctly when using
the most recent guideline (70% versus weighted average of 88%), while
fewer answered case 3 correctly when applying the older guideline (29%
versus weighted average of 79%). Agreement upon a BP target for each
question ranged from 46 to 63%, with most pharmacists recommending
<130/80 or < 140/90 mmHg across the four hypertension clinical cases.
Table 2
Evaluation of the usage of clinical practice guidelines in practice, teaching, and the
survey clinical cases.
Hypertensiona Dyslipidemiaa Asthmaa P value for the
interactionb
n = 48 n = 34 n = 28
Guidelines used
In Practice, n (%)c 0.922
Most recent guideline 31 (65) 21 (62) 18 (67)
Older guidelines 17 (35) 13 (38) 9 (33)
No response 0 0 1
P value within disease
state ¶
0.043 0.170 0.083
In Teaching, n (%)c 0.918
Most recent guideline 27 (75) 21 (72) 14 (78)




Do not teach this
disease state
3 2 7
Do not teach 1 1 1
No response 6 0 0
P value within disease
stated
0.003 0.016 0.018
In clinical cases, n (%)c 0.380
Most recent guideline 97 (67) 15 (54) 15 (68)




Did not answer case 27 0 0
P value within disease
stated
<0.001 0.705 0.088
a The most recent guideline for hypertension was ACC/AHA (2017) and older
guidelines only included JNC-8 (2014). For dyslipidemia, themost recent guideline
was ACC/AHA (2018) and older guidelines included ACC/AHA (2013), ACC
(2017), and AACE (2017). For asthma, the most recent guideline was GINA
(2018) and older guidelines only included ERP-3 (2007).
b Bivariate Chi Square Analysis investigated the interaction between disease state
and guideline selected using probability calculations. Counts for “Combination of
recent and older guidelines,” “Do not teach the disease state,” “No response,” “No
specific guidelines selected,” and “Did not answer case”were not included in statis-
tical analysis. Alpha was set to 0.01.
c n = number; % = percentages calculated using the total n of responses, not
including counts of “Do not teach the disease state,” “Do not teach,” “No response,”
and “Did not answer questions.” For High Blood pressure, the 48 survey respon-
dents could answer up to four clinical questions, resulting in a total n of 192.
d Univariate Chi Square Analysis was conducted within disease state to evaluate
whether observed counts of the most recent guideline and the total of older guide-
lines were different than expected if equal. Counts for “Combination of recent and
older guidelines,” “Do not teach the disease state,” “No response,” “No specific
guidelines selected,” and “Did not answer case”were not included in either statisti-
cal analysis or totals used to calculate percentages. Alpha was set to 0.01.
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3.1.4. Factors that influence overall adoption of new guidelines into clinical
practice
Thirty-five pharmacists (65% of the 54 survey respondents) answered
the final survey questions (data not shown) – these pharmacists had an-
swered survey questions for two out of the three disease states. Proportion-
ally, more pharmacists (n = 25/35, 71.4%, p = 0.017) reported to adopt
new guidelines into clinical practice within six months of release or as
soon as they have a chance to read them. Four primary reasons influenced
their adoption of new guidelines into practice; these included: (1) “If they
agree with it” (65.7%), (2) “ease of use” (51.4%), (3) “after learning
about it from a reliable organization” (51.4%), and (4) “if my clinic/organi-
zation mandates it” (42.9%).
4. Discussion
Clinical pharmacists are required to uphold the highest standards of in-
tegrity and honesty, always working in the best interest of patients. They
must commit to lifelong learning, self-assessment, and self-development,
as well as providing professional education to other healthcare
professions.24 It is vital to know which compilations of evidence are most
Table 3
Evaluation of pharmacist attitudes and awareness of clinical practice guidelines.
Hypertensiona Dyslipidemiaa Asthmaa P value for the
interactionb
n = 48 n = 34 n = 28
Length of time the most recent guideline has been used, n (%)c < 0.001
>1 year 20 (74) 2 (9) 9 (50)
<1 year 7 (26) 20 (91) 9 (50)
No response 4 0 1
N/A/− Using an older guideline 17 12 9
P value within disease stated 0.012 < 0.001 1.000
Pharmacists' knowledge of the most recent guideline, n(%)c < 0.001
I have read the summary/full report. 40 (95) 24 (71) 12 (43)
I am aware of some of the content, but have not read the summary or the full report. 1 (2) 8 (23) 12 (43)
I am aware of its existence, but not aware of its contents. 1 (2) 1 (3) 1 (3)
I am not aware of this guideline. 0 (0) 1 (3) 3 (11)
No response 6 0 0
P value within disease stated < 0.001 < 0.001 0.002
Reasons why the most recent guideline was selected, n (%)c 0.825
I agree with all or most of the recommendations
compared to other guidelines.
12 (44) 12 (55) 9 (50)
I always reference the most recently published guideline. 12 (44) 8 (36) 8 (44)
I do not agree with some or all of the recommendations in other guidelines. 1 (4) 1 (4) 0 (0.0)
It is the easiest to follow among the other published guidelines. 1 (4) 0 (0.0) 1 (6)
The clinic or organization I am employed at has mandated use of this guideline. 0 (0) 1 (4) 0 (0)
Other: Providers prefer 1 (4) 0 (0) 0 (0)
No response 4 0 1
N/A – Using an older guideline 17 12 9
P value within disease stated <0.001 <0.001 <0.001
Reasons why the most recent guideline was not selected, n (%)c < 0.001
I do not agree with the treatment recommendations made in these guidelines. 8 (35) 0 (0.0) 0 (0.0)
I am aware of the data but do not believe that it constitutes a guideline change at this time. 6 (26) 0 (0.0) 1 (8)
The providers at my clinic do not use these guidelines and, therefore, I do not either. 4 (17) 1 (8) 2 (17)
I am not very familiar with this guideline. 1 (4) 6 (50) 7 (58)
The quality measures in my workplace do not align with these guidelines. 2 (9) 0 (0) 0 (0.0)
I am not aware of the data supporting these guidelines. 0 (0.0) 1 (8) 1 (8)
I do not have time to read guidelines. 0 (0.0) 0 (0) 1 (8)
Other: Recommendations made on a smaller / less inclusive body of evidence 2 (9) 0 (0) 0 (0)
Other: Use the most recent guideline combined with the new guideline. 0 (0) 2 (17) 0 (0)
Other: Too new / Still reviewing the changes. 0 (0) 2 (17) 0 (0)
No response 3 2 0
N/A - Using the most recent guideline 31 22 9
P value within disease stated <0.001 0.002 <0.001
Pharmacists' level of agreement to having the most confidence in the specified guideline, mean rating (SD) –
Most recent guideline 3.9 (0.9) 4.0 (0.8) 3.9 (0.7)
Older guidelines 3.4 (1.3) 3.3 (0.7) 3.1 (1.0)
No response, n 13 2 2
P value within disease stated 0.097 0.001 0.007
Alpha was set to 0.01.
a The most recent guideline for hypertension was ACC/AHA (2017) and older guidelines only included JNC-8 (2014). For dyslipidemia, the most recent guideline was
ACC/AHA (2018) and older guidelines included ACC/AHA (2013), ACC (2017), and AACE (2017). For asthma, the most recent guideline was GINA (2018) and the older
guidelines only included ERP-3 (2007).
b Bivariate Chi Square Analysis investigated the interaction between disease state and pharmacist attitudes or awareness of clinical practice guidelines. Counts for “Do not
teach the disease state,” “No response,” and “Did not answer questions”were not included in totals. No comparison across diseases states was made for pharmacist's level of
agreement in having the most confidence in a guideline.
c SD = Standard Deviation; n = number; % = percentages calculated using the total n of responses, not including counts of “No response” and “N/A - Using the most
recent guideline.” Survey respondents could choose more than one response for reasons why or why not the most recent guideline was selected.
d Univariate Chi Square Analysis was conducted within disease state to evaluate whether the observed counts of pharmacist attitudes or awareness were different than
expected if equal. Counts for “No response,” and “N/A - Using themost recent guideline”were not included in totals. Wilcoxon signed-rank test investigated the difference in
agreement to having a high confidence level (5= Strongly agree to 1= Strongly disagree) in the most recent as compared to older guidelines when rated by the same phar-
macists. Alpha was set to 0.01.
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valid to ensure proper teaching and modeling of practice. With the cessa-
tion of NHLBI producing guidelines, several different organizations have
published practice recommendations within respective disease states over
the last ten years. Havingmultiple guidelines for a single disease can clearly
cause confusion, debate, and even legal ramifications. It can be difficult for
clinicians to keep up with the most current literature, especially for a broad
variety of chronic disease states. Many rely on the expert summation of
evidence-based practice guidelines. While personally reviewing the evi-
dence is always best, many pharmacists would benefit from knowing
their peers' trusted sources. Therefore, this survey was used to explore
how clinical pharmacists are incorporating these guidelines into their prac-
tices and serves as a pilot to future related studies.
These preliminary results suggest the majority of pharmacists reported
using the most recent guidelines in practice and teaching, although with
variable rates. A higher proportion of pharmacists reported using the
most recent guideline for hypertension for more than one year as compared
to dyslipidemia and asthma. However, both dyslipidemia and asthma
guidelines were released in 2018 and therefore at the time of this survey,
had only been published for <1 year. The reasons for referencing the
most recent guideline were similar across all three disease states, whereas
reasons for not using the most recent guideline was different for hyperten-
sion as compared to dyslipidemia and asthma. In addition, pharmacists'
knowledge of the most recent guideline varied across disease state; the
highest proportion of pharmacists had read the summary/full report for hy-
pertension, but fewest for asthma.
Applicable to teaching, an article by Brown, highlighted the importance
of educating pharmacy students to critically analyze the recommendations
made in clinical practice guidelines vs simply trusting and memorizing
them. This is emphasized since varying levels of evidence go into making
each recommendation and somewill be stronger than others, especially be-
tween a variety of guideline authors.25 This strategy is an important skill set
for future pharmacists to develop as multiple guidelines from varying orga-
nizations are published.
There was inconsistent application of the most recent guidelines in the
clinical cases. This was especially apparent regarding asthma guidelines,
where most respondents reported using GINA in practice, but then an-
swered the case with ERP-3 recommendations. Moreover, for asthma, the
lowest proportion of pharmacists answered the case study correctly when
using the most recent guideline, whereas the highest proportion answered
correctly when using the older guideline, as compared to hypertension
and dyslipidemia.
Regarding the four hypertension cases, there were considerable differ-
ences in identifying the correct BP goal, despite themajority of pharmacists
referencing ACC/AHA 2017. While clinical pharmacists are known to excel
at following guidelines, results suggest that pharmacists did not fully apply
the new guidelines; there were different interpretations of the guidelines as
they were applied to different clinical situations; and/or older recommen-
dations were thought to still be current. This is similar to results also seen
by Bucheit et al.20 who found 92.3% clinical pharmacists reported reading
the summary or full report of the 2013 ACC/AHA cholesterol guidelines but
application of the guidelines showed less congruency with just 72.9% of
clinical pharmacists able to identify the four statin benefit groups. Simi-
larly, in a study by Lowenstern et al., clinician responses to hypothetical
cases assessing for statin prescribing did not always agree with observed
prescribing rates for similar clinical cases where agreement was highest at
64% among the statin benefit groups.26 In our study, specific cases were
used to highlight the differences in treatment recommendations depending
on the guideline utilized. Our results further support the findings of Bucheit
et al.20 and Lowenstern et al.26 that there are important knowledge and ap-
plication gaps or even clinical inertia when applying clinical practice guide-
lines. Perhaps ingrained practice habits were difficult to overcome while
trying to apply the most current guidelines to case questions. It is also pos-
sible that clinical pharmacists believed they should select the most current
guidelines, because it is professionally expected to always be “up to date”.
Practice habits in answering the survey's case questions, however,
portrayed their true guideline allegiance. It is also possible some pharma-
cists blended recommendations from different guidelines or used clinical
judgment based on an individual patient's situation. The use of clinical
judgment was thought to be a major factor in a study by Ramsaran et al.
that identified common reasons for non-adherence to the 2013 ACC/AHA
cholesterol guidelines.27 An article in the Journal of the American College
of Cardiology recently highlighted the significant impact therapeutic iner-
tia has on cardiovascular disease.28 In this article, authors recognized that
a more effective approach for educating clinicians on guidelines is to pro-
vide face-to-face education and feedback on the clinician's performance
rather than just encouraging clinicians to familiarize themselves with prac-
tice guidelines. Future studies should focus on why pharmacists make rec-
ommendations that are not consistent with the latest guidelines (e.g.
patient variables, personal experience, different interpretations of the
guidelines, disagreement with some but not all guideline recommenda-
tions, etc.) and strategies for overcoming clinical inertia.
4.1. Limitations
The primary limitation to this exploratory study was the low response
rate. While a large pool of pharmacists was recruited via e-mail, this
Table 4
Evaluation of the correctness of responses to the survey clinical cases based on practice guideline selected or the most recent guideline for each disease state.
Hypertension† Dyslipidemiaa Asthmaa P value for the
interactionb
n = 192 n = 34 n = 27
Based on guideline selected, n (%)c <0.001
Most recent guideline - Correct 81 (84) 8 (53) 4 (27)
Most recent guideline - Incorrect 16 (16) 7 (47) 11 (73)
Older guidelines - Correct 31 (65) 11 (85) 7 (100.0)
Older guidelines - Incorrect 17 (35) 2 (15) 0 (0.0)
No specific guideline selected 20 6 6
Did not answer case 27 0 0
P value within disease stated 0.011 0.077 0.001
a The most recent guideline for hypertension was ACC/AHA (2017) and older guidelines only included JNC-8 (2014). For dyslipidemia, the most recent guideline was
ACC/AHA (2018) and older guidelines included ACC/AHA (2013), ACC (2017), and AACE (2017). For asthma, the most recent guideline was GINA (2018) and the older
guidelines only included ERP-3 (2007). For High Blood pressure, the 48 survey respondents could answer up to four clinical questions, resulting in a total n of 192.
b Bivariate Chi Square Analysis investigated the interaction between disease states and correctness of response based on guideline applied to survey clinical cases. Counts
for “No specific guideline selected” and “Did not answer case” were not included in totals. Alpha was set to 0.01.
c n = number; % = percentages calculated using the total n of responses, not including counts of “No specific guideline provided” and “No response.” Total n for Hy-
pertension was higher due to four clinical questions being asked in the survey as compared to one for Dyslipidemia and Asthma.
d Bivariate Chi Square Analysis within disease investigated the interaction between guideline selected and correctness of response. When the recommendation from the
most recent guideline was used only, univariate Chi Square Analysis was conductedwithin disease state to evaluate correctness of response. Counts for “No specific guideline
selected” and “Did not answer case” were not included in totals. Alpha was set to 0.01.
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study truly employed a voluntary response sample. That is, researchers
made no direct or personal contacts with potential survey respondents,
and did not include an incentive for participation. In addition, it is also
not possible to know how many pharmacists actually received the survey
email. Low response rate may also have been influenced by the ACCP
PRN requirement of limiting the survey to a two-week period.
Another factor whichmay have reduced response rate was that this sur-
vey captured data on three chronic disease states that previously had pub-
lished guidelines from NHLBI. It is possible that narrowing the survey to
one single disease state would have made it more focused and, therefore,
may have improved the number of clinicians who felt qualified to complete
the survey. In addition, a smaller number of pharmacists completed the dys-
lipidemia and asthma portions of the survey. Presenting hypertension ques-
tions first in the survey could have contributed to this outcome. The higher
response rate for hypertension also could be attributed tomore pharmacists
managing hypertension than asthma in practice, as related to the high prev-
alence of hypertension in the U.S.29 Therefore, a larger follow-up study
could include multiple surveys (one over each disease state) over longer
survey periods, or even a separate study for each disease state.
It should be pointed out that it is common for response rates of web sur-
veys to be lower than other surveymodes.30 In support of this, the National
Pharmacist Workforce Study 201931 had a response rate of 5.8%, and a
2020 membership survey as conducted by the ACCP PRN had a response
rate around 12% (B. Zobeck, personal communication, March 17, 2021).
Coincidentally, 261 pharmacists responded Ambulatory Care as their pri-
mary employment practice setting in the National Pharmacist Workforce
Study 2019, while 259 pharmacists responded to the 2020 ACCP PRN
membership survey. Using the average of these as the number of pharma-
cists in this practice area who are willing to answer online surveys, then
the calculation of response rate of this study increases from 2.3% to 18.5%.
In evaluating the demographics of the survey respondents who were re-
cruited from the ACCP PRN, it was not surprising that a larger proportion in
this study were females; this is similar to the finding by the National Phar-
macist Workforce Study 201931that the majority of pharmacists in full- and
part-time practice were female. In contrast to the National Pharmacist
Workforce Study 2019, this study found a higher percentage of survey re-
spondents were from the Midwest and fewer were from the South. In addi-
tion, more survey respondents practiced in medical or hospital settings as
compared to a community pharmacy setting31While the actual distribution
of ACCP PRN pharmacists nationwide is not reported in the National Phar-
macist Workforce Study 2019,31 the difference of job setting is not surpris-
ing due to the nature of the work of Ambulatory Care pharmacists.
Pharmacists in this study were on average fairly early in their careers,
with an average age in the mid-thirties and having practiced ≤10 years.
Similarly, most respondents of the 2020 ACCP PRN membership survey
had been members of the ACCP (77.2%) and Ambulatory Care PRN
(83.0%) for less than ten years (B. Zobeck, personal communication,
March 17, 2021). Likewise, the highest proportion of respondents to the
National Pharmacist Workforce Study 201931 was found between 31 and
40 years old (28.9%). This also opens questions for further research: Are
younger pharmacists more active in ACCP PRNs? Are younger pharmacists
more likely to participate in online surveys? Were younger pharmacists
taught some topics differently than older pharmacists; all would have
learned asthma well after the NHLBI 2007 guidelines and would have
known GINA, while more seasoned pharmacists still recall the older guide-
line? Do older pharmacists get “set in their ways”? Why did younger phar-
macists claim to use GINA 2018, but went on to utilize the 2007 guidelines
in the clinical cases? These questions should be explored in future research.
To account for multiple tests conducted on the same subjects, the signif-
icance level was lowered from the standard alpha of 0.05 to 0.01 to de-
crease the Type I error. Researchers recognized that a lower alpha
decreased power, which was already lowered by the small sample size.
However, this trade-off was deemed by the authors to be necessary, so
that changing the response of one pharmacist was less likely to result in
an incorrect significant finding. Overall, this exploratory study revealed im-
portant differences in pharmacist utilization and application of guidelines
despite its small sample size, which generates the impetus for further schol-
arly projects on this topic.
To our knowledge, this is the first study that has surveyed clinical phar-
macists about all of the most recently published guidelines within a disease
state. Despite the small sample size, overall survey results suggest clinical
pharmacists may not always select the most recent practice guidelines,
and application of guidelines is not always consistent. This is an important
initial finding that warrants larger research efforts. Although clinical judg-
ment is a part of practicing medicine, discord among use of practice guide-
lines across the profession is confusing for patients and clinicians. In all
three of these disease states, different professional organizations have pub-
lished guidelines over the last ten years. Instead of working separately, ide-
ally organizations could come together to create a more unified approach
that would enhance unity upon adoption of new iterations. This prelimi-
nary surveymay generate future, larger studies focusing on each individual
disease state. This survey also excluded prescribers such as physicians, ad-
vanced nurse practitioners, and physician assistants. These clinicians may
have different experiences or answers, and, therefore, should be considered
for future studies. In addition, researchers may investigate whether the rep-
utation of individual organizations influences guideline adoption. As pay-
for-performance measures are implemented, it is hypothesized this factor
could further influence adoption of guideline-based recommendations,
but again may cause some controversy based on which guideline is chosen
if there are inconsistencies in clinical practice.
5. Conclusion and relevance
This exploratory survey of clinical pharmacists involved in the manage-
ment of hypertension, dyslipidemia, and/or asthma explores the aware-
ness, attitudes, and application of guidelines within each disease state.
Although themajority of pharmacists reported using themost recent guide-
lines for practice and teaching, there is still substantial variability among
application of the guidelines. Identifying practice trends can inform phar-
macists to peer preferences. Identifying factors that most influence clinical
pharmacists to utilize clinical practice guidelines can inform guideline au-
thors and assist in implementation of future guidelines. Further studies
are warranted to more definitively determine factors influencing guideline
preference and usage.
Declaration of Competing Interest




A.1. Hypertension Clinical Cases
Which blood pressure goal would you choose for the following patients?
1. 50 year-old adult male with 10-year ASCVD risk of 12%
2. 34 year-old adult female with 10-year ASCVD risk of 3%
3. 75 year-old adult male with CAD and no other comorbidities
4. 42 year-old adult female with diabetes and 10-year ASCVD risk of 5%
Answers and percent correct for each hypertension case by guideline:
1. <130/80 and 89% (ACC/AHA 2017), <140/90 and 86% (“JNC-8”)
2. <130/80 and 70% (ACC/AHA 2017), <140/90 and 80% (“JNC-8”)
3. <130/80 and 87% (ACC/AHA 2017), <150/90 and 29% (“JNC-8”)
4. <130/80 and 89% (ACC/AHA 2017), <140/90 and 70% (“JNC-8”)
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A.2. Dyslipidemia Clinical Case
What cholesterol treatment goal(s) and pharmacotherapy would you
choose for the following patient?
1. 54 year-old adult male with hypertension and 10-year ASCVD risk of
12%, HDL = 43 mg/dL, LDL = 135 mg/dL, and non-HDL = 150 mg/
dL.
Answers for dyslipidemia case by guideline:
1. Moderate intensity (ACC/AHA 2018), moderate to high intensity (ACC/
AHA 2013)
A.3. Asthma Clinical Case
1. In an adult with mild (intermittent) asthma, which of the following is the
most appropriate treatment?
a. Short-acting beta 2 agonist PRN
b. Short-acting beta-2 agonist PRN AND low-dose inhaled corticosteroid
scheduled
c. Short-acting beta 2 agonist PRN AND low-dose inhaled corticosteroid
scheduled AND long-acting beta 2 agonist scheduled
d. None of the above
Answers for asthma case by guideline:
1. (b) Short-acting beta-2 agonist PRN AND low-dose inhaled corticoste-
roid scheduled (GINA 2018), (a) Short-acting beta-2 agonist PRN
(EPR-3)
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